Publication | Open Access

Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models

Radiation TherapyMedicineRadionuclide TherapyPharmacologyTreatment ResponseHead And Neck CancerAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyCancer ResearchGlutaminase Inhibition